Shares in Inovio Pharmaceuticals (NSDQ:INO) jumped more than 10% after it announced that it is launching a Phase III clinical study of its investigational DNA immunotherapy candidate designed to treat cervical dysplasia caused by human papillomavirus. The moves comes after the FDA lifted a hold that it placed on the clinical program in October last year. At […]
Inovio Pharmaceuticals
FDA delays Inovio phase III trial of DNA immunotherapy candidate
Inovio Pharmaceuticals (NSDQ:INO) said today that the FDA placed a hold on its proposed Phase III clinical program for its investigational DNA immunotherapy candidate designed to treat pre-cancers and cancers caused by human papillomavirus. The California-based company completed a randomized, double-blind Phase II trial of the candidate in July 2014, evaluating the DNA immunotherapy treatment in women […]
Inovio Pharma picks up Bioject
Inovio Pharmaceuticals said today it paid $5.5 million for the assets of Bioject Medical Technologies including its needle-free jet injection tech, devices and intellectual property With the acquisition, Inovio said it will advance an integrated non-invasive delivery device combining the acquired jet injection tech with its own needle-free skin-surface electroporation tech. Inovio said it’s goal […]
